Research output per year
Research output per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Doctor of Philosophy, The development of quantitative live cell imaging techniques and their applications in the study of inter-cellular communication and sarcoma cell motility, CRUK Cancer Research UK
Apr 1999 → Apr 2003
Award Date: 1 Oct 2003
Bachelor of Science, Human Sciences, UCL University College London
Sept 1995 → Jun 1998
Award Date: 1 Sept 1998
External positions
Postdoctoral Research Scientist, Kyoto University
Apr 2006 → Dec 2007
Japan Society for the Promotion of Science (JSPS) Research Fellow, Kyoto University
Apr 2004 → Mar 2006
Horizontal Research Medical Organization (HMRO) Research Scientist, Kyoto University
Jul 2003 → Mar 2004
Fingerprint
Dive into the research topics where James Monypenny of Pitmilly is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
The MondoA-dependent TXNIP/GDF15 1 axis predicts oxaliplatin response in colorectal adenocarcinomas. Oxaliplatin-induced immunogenicity through the regulation of the TXNIP/GDF15 axis
Deng, J., Pan, T., Wang, D., Hong, Y., Liu, Z., Zhou, X., An, Z., Li, L., Alfano, G., Li, G., Dolcetti, L., Evans, R., Vicencio Bustamante, J., Vlckova, P., Chen, Y., Monypenny of Pitmilly, J., Araujo De Carvalho Gomes, C., Weitsman, G., Ng, K. & McCarthy, C. & 11 others, , 3 Jul 2024, (Accepted/In press) In: EMBO Molecular Medicine.Research output: Contribution to journal › Article › peer-review
Open Access -
The MondoA-dependent TXNIP/GDF15 axis predicts oxaliplatin response in colorectal adenocarcinomas
Deng, J., Pan, T., Wang, D., Hong, Y., Liu, Z., Zhou, X., An, Z., Li, L., Alfano, G., Li, G., Dolcetti, L., Evans, R., Vicencio, J. M., Vlckova, P., Chen, Y., Monypenny, J., Gomes, C. A. D. C., Weitsman, G., Ng, K. & McCarthy, C. & 11 others, , 12 Sept 2024, In: EMBO Molecular Medicine. 16, 9, p. 2080-2108 29 p.Research output: Contribution to journal › Article › peer-review
Open Access -
HER2 mediates PSMA/mGluR1-driven resistance to the DS-7423 dual 2 PI3K/mTOR inhibitor in PTEN wild-type prostate cancer models: PTEN-wt PCa overcomes PI3K inhibition via mGluR1 signaling
Gómez, V., Galazi, M., Weitsman, G., Monypenny of Pitmilly, J., Al-Salemee, F., Barber, P., Ng, K., Beatson, R., Szokol, B., Orfi, L., Mullen, G., Vanhaesebroeck, B., Chowdhury, S., Leung, H. Y. & Ng, T., 19 Jan 2022, (Accepted/In press) In: MOLECULAR CANCER THERAPEUTICS.Research output: Contribution to journal › Article › peer-review
-
HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models
Gómez, V., Galazi, M., Weitsman, G., Monypenny, J., Al-Salemee, F., Barber, P. R., Ng, K., Beatson, R., Szokol, B., Orfi, L., Mullen, G., Vanhaesebroeck, B., Chowdhury, S., Leung, H. Y. & Ng, T., 1 Apr 2022, In: Molecular Cancer Therapeutics. 21, 4, p. 667-676 10 p.Research output: Contribution to journal › Article › peer-review
Open Access8 Citations (Scopus) -
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans
Vicencio Bustamante, J., Evans, R., Green, R., An, Z., Deng, J., Treacy, C., Mustapha, R., Monypenny of Pitmilly, J., Costoya , C., Lawler, K., Ng, K., Desouza, K., Coban, O., Gomez, V., Clancy, J., Chen, S., Chalk, A., Wong, F., Gordon, P. & Savage, C. & 20 others, , 28 Mar 2022, In: Cell Death & Disease. 13, 3, 274 .Research output: Contribution to journal › Article › peer-review
Open AccessFile15 Citations (Scopus)148 Downloads (Pure)